Ruiyi Tang1, Qi Yu2. 1. Department of Obstetrics and Gynecology, Peking Union Medical College Hospital, Peking Union Medical College, Chinese Academy of Medical Science, Beijing, 100730, People's Republic of China. 2. Department of Obstetrics and Gynecology, Peking Union Medical College Hospital, Peking Union Medical College, Chinese Academy of Medical Science, Beijing, 100730, People's Republic of China. yuqi2008001@sina.com.
Abstract
PURPOSE: To investigate the potential etiologies of premature ovarian insufficiency (POI) and diminished ovarian reserve (DOR). METHODS: Fourteen women with sporadic POI and 6 women with DOR were enrolled. We used whole-exome sequencing (WES) and bioinformatics analysis to identify variants in a subset of 599 selected POI candidate genes. The identified genes were subjected to gene ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) enrichment and protein-protein interaction (PPI) network analyses to uncover key genes and pathways. RESULTS: Among the 20 patients, 79 heterozygous variants were detected in 49 genes, which were classified as "likely pathogenic" or "variants of uncertain significance" according to the guidelines of the American College of Medical Genetics and Genomics. Most patients (17/20) carried two or more variants. Monoacylglycerol O-acyltransferase 1 mutations were found in six patients, and cytochrome P450 family 26 subfamily B member 1 and Bardet-Biedl syndrome 9 mutations were each found in four patients. Some variants were shared between DOR and POI. Enrichment analyses showed that the identified genes participate in key ovarian processes, such as follicular development, gonadal development, meiosis, Fanconi anemia, homologous recombination, and transforming growth factor β signaling. A PPI network revealed interactions between these proteins. CONCLUSION: Premature ovarian function decline may be polygenic, and overlap exists between the genetic backgrounds of DOR and POI. WES and in silico analyses may be a useful clinical tool for etiological diagnosis and risk prediction for high-risk women in the future.
PURPOSE: To investigate the potential etiologies of premature ovarian insufficiency (POI) and diminished ovarian reserve (DOR). METHODS: Fourteen women with sporadic POI and 6 women with DOR were enrolled. We used whole-exome sequencing (WES) and bioinformatics analysis to identify variants in a subset of 599 selected POI candidate genes. The identified genes were subjected to gene ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) enrichment and protein-protein interaction (PPI) network analyses to uncover key genes and pathways. RESULTS: Among the 20 patients, 79 heterozygous variants were detected in 49 genes, which were classified as "likely pathogenic" or "variants of uncertain significance" according to the guidelines of the American College of Medical Genetics and Genomics. Most patients (17/20) carried two or more variants. Monoacylglycerol O-acyltransferase 1 mutations were found in six patients, and cytochrome P450 family 26 subfamily B member 1 and Bardet-Biedl syndrome 9 mutations were each found in four patients. Some variants were shared between DOR and POI. Enrichment analyses showed that the identified genes participate in key ovarian processes, such as follicular development, gonadal development, meiosis, Fanconi anemia, homologous recombination, and transforming growth factor β signaling. A PPI network revealed interactions between these proteins. CONCLUSION:Premature ovarian function decline may be polygenic, and overlap exists between the genetic backgrounds of DOR and POI. WES and in silico analyses may be a useful clinical tool for etiological diagnosis and risk prediction for high-risk women in the future.
Authors: Liliana Catherine Patiño; Isabelle Beau; Carolina Carlosama; July Constanza Buitrago; Ronald González; Carlos Fernando Suárez; Manuel Alfonso Patarroyo; Brigitte Delemer; Jacques Young; Nadine Binart; Paul Laissue Journal: Hum Reprod Date: 2017-07-01 Impact factor: 6.918
Authors: B Alvaro Mercadal; R Imbert; I Demeestere; C Gervy; A De Leener; Y Englert; S Costagliola; A Delbaere Journal: Hum Reprod Date: 2015-03-06 Impact factor: 6.918
Authors: Stella Tran; Xiang Zhou; Christine Lafleur; Michael J Calderon; Buffy S Ellsworth; Sarah Kimmins; Ulrich Boehm; Mathias Treier; Derek Boerboom; Daniel J Bernard Journal: Mol Endocrinol Date: 2013-01-22
Authors: L Webber; M Davies; R Anderson; J Bartlett; D Braat; B Cartwright; R Cifkova; S de Muinck Keizer-Schrama; E Hogervorst; F Janse; L Liao; V Vlaisavljevic; C Zillikens; N Vermeulen Journal: Hum Reprod Date: 2016-03-22 Impact factor: 6.918
Authors: Sue Richards; Nazneen Aziz; Sherri Bale; David Bick; Soma Das; Julie Gastier-Foster; Wayne W Grody; Madhuri Hegde; Elaine Lyon; Elaine Spector; Karl Voelkerding; Heidi L Rehm Journal: Genet Med Date: 2015-03-05 Impact factor: 8.822
Authors: R Morales; B Lledo; J A Ortiz; F M Lozano; E M Garcia; A Bernabeu; A Fuentes; R Bernabeu Journal: J Assist Reprod Genet Date: 2022-10-08 Impact factor: 3.357
Authors: Blair R McCallie; Mary Haywood; Michelle M Denomme; Rachel Makloski; Jason C Parks; Darren K Griffin; William B Schoolcraft; Mandy G Katz-Jaffe Journal: J Assist Reprod Genet Date: 2021-03-30 Impact factor: 3.357
Authors: Aleksandra V Moiseeva; Varvara A Kudryavtseva; Vladimir N Nikolenko; Marine M Gevorgyan; Ara L Unanyan; Anastassia A Bakhmet; Mikhail Y Sinelnikov Journal: J Ovarian Res Date: 2021-08-06 Impact factor: 4.234